GlassScriptPhysician profile
Kacy H Nesmith
NPI 1023408523
$1,979.90
in general payments reported to CMS, 2019-2025
33 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.27 · 2022: $119 · 2023: $265 · 2024: $249 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.90 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $224.77 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.22 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $140.35 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.57 | 2025 | Xifaxan |
| Amgen INC. | $94.24 | 2022-2025 | Prolia, Evenity, Otezla |
| Dexcom, INC. | $71.02 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $70.89 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $68.87 | 2022-2025 | Airsupra, Farxiga |
| Corcept Therapeutics | $67.04 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $66.63 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $52.05 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $45.38 | 2025 | Voquezna |
| Lundbeck LLC | $38.67 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $31.96 | 2023-2024 | Quviviq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $25.80 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $25.44 | 2023 | Sunosi |
| Radius Health, INC. | $24.93 | 2025 | Tymlos |
| Scilex Pharmaceuticals INC. | $22.52 | 2023 | Ztlido |
| Ironshore Pharmaceuticals INC. | $21.89 | 2024 | |
| Verona Pharma, INC. | $21.62 | 2025 | Ohtuvayre |
| Sanofi Pasteur INC. | $21.42 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.08 | 2022 | |
| Ardelyx, INC. | $20.32 | 2025 | Ibsrela |
| Amarin Pharma, INC. | $17.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.12 | 2022 | |
| Abbott Laboratories | $17.01 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $16.84 | 2025 | Verquvo |
| Glaxosmithkline, LLC. | $16.48 | 2024 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $15.88 | 2025 | Nexletol |
| Supernus Pharmaceuticals, INC. | $14.98 | 2023 | Qelbree |
| Sumitomo Pharma America, INC. | $13.10 | 2023 | Gemtesa |
| Corium, LLC | $10.24 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacy Nesmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.